Young-Onset Dementia

Abstract

Young-onset dementia is a neurologic syndrome that affects behavior and cognition of patients younger than 65 years of age. Although frequently misdiagnosed, a systematic approach, reliant upon attainment of a detailed medical history, a collateral history, neuropsychological testing, laboratory studies, and neuroimaging, may facilitate earlier and more accurate diagnosis with subsequent intervention. The differential diagnosis of young-onset dementia is extensive and includes early-onset forms of adult neurodegenerative conditions including Alzheimer's disease, vascular dementia, frontotemporal dementia, Lewy body dementias, Huntington's disease, and prion disease. Late-onset forms of childhood neurodegenerative conditions may also present as young-onset dementia and include mitochondrial disorders, lysosomal storage disorders, and leukodystrophies. Potentially reversible etiologies including inflammatory disorders, infectious diseases, toxic/metabolic abnormalities, transient epileptic amnesia, obstructive sleep apnea, and normal pressure hydrocephalus also represent important differential diagnostic considerations in young-onset dementia. This review will present etiologies, diagnostic strategies, and options for management of young-onset dementia with comprehensive summary tables for clinical reference.

Keywords

young-onset dementia - early-onset dementia - neurodegenerative disease - dementia/reversible

• References

• 1 Harvey RJ, Rossor MN, Skelton-Robinson M , et al. Young onset dementia: epidemiology, clinical symptoms, family burden, support and outcome. London, England: Dementia Research Group; 1998
• 2 Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002; 58 (11) 1615-1621
• 3 Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry 2003; 74 (9) 1206-1209
• 4 Mendez MF. The accurate diagnosis of early-onset dementia. Int J Psychiatry Med 2006; 36 (4) 401-412
• 5 Papageorgiou SG, Kontaxis T, Bonakis A, Kalfakis N, Vassilopoulos D. Frequency and causes of early-onset dementia in a tertiary referral center in Athens. Alzheimer Dis Assoc Disord 2009; 23 (4) 347-351
• 6 Kelley BJ, Boeve BF, Josephs KA. Young-onset dementia: demographic and etiologic characteristics of 235 patients. Arch Neurol 2008; 65 (11) 1502-1508
• 7 Harris PG, Keady J. Living with early onset dementia: exploring the experience and developing evidence-based guidelines for practice. Alzheimers Care Quarterly
• 8 Sampson EL, Warren JD, Rossor MN. Young onset dementia. Postgrad Med J 2004; 80 (941) 125-139
• 9 Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (3) 189-198
• 10 Nasreddine ZS, Phillips NA, Bédirian V , et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53 (4) 695-699
• 11 Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol 2010; 9 (8) 793-806
• 12 Knopman DS, DeKosky ST, Cummings JL , et al; Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: diagnosis of dementia (an evidence-based review). Neurology 2001; 56 (9) 1143-1153
• 13 Warren JD, Schott JM, Fox NC , et al. Brain biopsy in dementia. Brain 2005; 128 (Pt 9) 2016-2025
• 14 Sperling RA, Aisen PS, Beckett LA , et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3) 280-292
• 15 Mendez MF. Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD. Arch Med Res 2012; 43 (8) 677-685
• 16 Snider BJ, Fagan AM, Roe C , et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66 (5) 638-645
• 17 Bird TD. Alzheimer disease overview. GeneReviews [Internet]. . Seattle, WA: University of Washington, Seattle; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1161/ . Accessed September 12, 2013
• 18 Monsell SE, Mock C, Roe CM , et al. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology 2013; 80 (23) 2121-2129
• 19 Wattmo C, Wallin AK, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord 2011; 25 (1) 63-72
• 20 Sinforiani E, Pasotti C, Chiapella L, Malinverni P, Zucchella C. Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit. Aging Clin Exp Res 2012; 24 (2) 193-196
• 21 Eikermann-Haerter K, Yuzawa I, Dilekoz E, Joutel A, Moskowitz MA, Ayata C. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome mutations increase susceptibility to spreading depression. Ann Neurol 2011; 69 (2) 413-418
• 22 Kinnecom C, Lev MH, Wendell L , et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007; 68 (17) 1411-1416
• 23 Liem MK, Lesnik Oberstein SA, Haan J , et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: progression of MR abnormalities in prospective 7-year follow-up study. Radiology 2008; 249 (3) 964-971
• 24 Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9 (7) 689-701
• 25 Cotrutz CE, Indrei A, Bădescu L , et al. Electron microscopy analysis of skin biopsies in CADASIL disease. Rom J Morphol Embryol 2010; 51 (3) 455-457
• 26 Lesnik Oberstein SAJ, Boon EMJ, Terwindt GM. CADASIL. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2012. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1500/ . Accessed September 12, 2013
• 27 Biffi A, Greenberg SM. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol 2011; 7 (1) 1-9
• 28 del Río-Espínola A, Mendióroz M, Domingues-Montanari S , et al. CADASIL management or what to do when there is little one can do. Expert Rev Neurother 2009; 9 (2) 197-210
• 29 Athyros VG, Tziomalos K, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Curr Opin Cardiol 2010; 25 (4) 406-410
• 30 Biffi A, Halpin A, Towfighi A , et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010; 75 (8) 693-698
• 31 Fernández-Matarrubia M, Matías-Guiu JA, Moreno-Ramos T, Matías-Guiu J. Behavioural variant frontotemporal dementia: Clinical and therapeutic approaches. Neurologia 2013; ; [Epub ahead of print]
• 32 Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology 2004; 62 (3) 506-508
• 33 Schroeter ML, Neumann J. Combined imaging markers dissociate Alzheimer's disease and frontotemporal lobar degeneration – an ALE meta-analysis. Front Aging Neurosci 2011; 3: 10
• 34 Van Swieten JC, Rosso SM, Heutink P. MAPT-related disorders. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2010. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1505/ . Accessed September 12, 2013
• 35 Hsiung GR, Feldman HH. GRN-related frontotemporal dementia. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1371/ . Accessed September 12, 2013
• 36 Seltman RE, Matthews BR. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 2012; 26 (10) 841-870
• 37 McCarter SJ, St Louis EK, Boeve BF. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep 2012; 12 (2) 182-192
• 38 McKeith IG, Dickson DW, Lowe J , et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65 (12) 1863-1872
• 39 Brown RG, Lacomblez L, Landwehrmeyer BG , et al; NNIPPS Study Group. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133 (Pt 8) 2382-2393
• 40 Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. J Neurol Neurosurg Psychiatry 2000; 68 (4) 434-440
• 41 Massey LA, Micallef C, Paviour DC , et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012; 27 (14) 1754-1762
• 42 Meeus B, Theuns J, Van Broeckhoven C. The genetics of dementia with Lewy bodies: what are we missing?. Arch Neurol 2012; 69 (9) 1113-1118
• 43 Stemberger S, Scholz SW, Singleton AB, Wenning GK. Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiol Aging 2011; 32 (10) e5-e14
• 44 Warby SC, Graham RK, Hayden MR. Huntington disease. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2010. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1305/ . Accessed September 12, 2013
• 45 Bates G, Harper P, Jones L. Huntington's Disease. New York, NY: Oxford University Press; 2002
• 46 Biglan KM, Ross CA, Langbehn DR , et al; PREDICT-HD Investigators of the Huntington Study Group. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009; 24 (12) 1763-1772
• 47 Guo Z, Rudow G, Pletnikova O , et al. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov Disord 2012; 27 (11) 1379-1386
• 48 Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009; 3 (3) CD006456
• 49 Sikorska B, Knight R, Ironside JW, Liberski PP. Creutzfeldt-Jakob disease. Adv Exp Med Biol 2012; 724: 76-90
• 50 Vitali P, Maccagnano E, Caverzasi E , et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology 2011; 76 (20) 1711-1719
• 51 Rosenbloom MH, Atri A. The evaluation of rapidly progressive dementia. Neurologist 2011; 17 (2) 67-74
• 52 Mastrianni J. Genetic prion disease. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2010. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1229/ . Accessed September 12, 2013
• 53 Baugh CM, Stamm JM, Riley DO , et al. Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. Brain Imaging Behav 2012; 6 (2) 244-254
• 54 McKee AC, Cantu RC, Nowinski CJ , et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009; 68 (7) 709-735
• 55 Manyam BV, Walters AS, Narla KR. Bilateral striopallidodentate calcinosis: clinical characteristics of patients seen in a registry. Mov Disord 2001; 16 (2) 258-264
• 56 Benke T, Karner E, Seppi K, Delazer M, Marksteiner J, Donnemiller E. Subacute dementia and imaging correlates in a case of Fahr's disease. J Neurol Neurosurg Psychiatry 2004; 75 (8) 1163-1165
• 57 Manyam BV, Bhatt MH, Moore WD, Devleschoward AB, Anderson DR, Calne DB. Bilateral striopallidodentate calcinosis: cerebrospinal fluid, imaging, and electrophysiological studies. Ann Neurol 1992; 31 (4) 379-384
• 58 Sobrido MJ, Coppola G, Oliveira J, Hopfer S, Geschwind DH. Primary familial brain calcification. GeneReviews [Internet]. Seattle, WA: University of Washington; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1421/ . Accessed September 12, 2013
• 59 Lazăr M, Ion DA, Streinu-Cercel A, Bădărău AI. Fahr's syndrome: diagnosis issues in patients with unknown family history of disease. Rom J Morphol Embryol 2009; 50 (3) 425-428
• 60 Hirano M, Ricci E, Koenigsberger MR , et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992; 2 (2) 125-135
• 61 Hirano M, DiMauro S. Clinical features of mitochondrial myopathies and encephalomyopathies. In: Lane RJM, , ed. Handbook of Muscle Disease. New York, NY: Marcel Dekker; 1996: 479-504
• 62 Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Opthalmol 1958; 60 (2) 280-289
• 63 Finsterer J. Hematological manifestations of primary mitochondrial disorders. Acta Haematol 2007; 118 (2) 88-98
• 64 Ito H, Mori K, Harada M , et al. Serial brain imaging analysis of stroke-like episodes in MELAS. Brain Dev 2008; 30 (7) 483-488
• 65 Orcesi S, Gorni K, Termine C , et al. Bilateral putaminal necrosis associated with the mitochondrial DNA A8344G myoclonus epilepsy with ragged red fibers (MERRF) mutation: an infantile case. J Child Neurol 2006; 21 (1) 79-82
• 66 Ito S, Shirai W, Asahina M, Hattori T. Clinical and brain MR imaging features focusing on the brain stem and cerebellum in patients with myoclonic epilepsy with ragged-red fibers due to mitochondrial A8344G mutation. AJNR Am J Neuroradiol 2008; 29 (2) 392-395
• 67 Serrano M, García-Silva MT, Martin-Hernandez E , et al. Kearns-Sayre syndrome: cerebral folate deficiency, MRI findings and new cerebrospinal fluid biochemical features. Mitochondrion 2010; 10 (5) 429-432
• 68 Kaufmann P, Pascual JM, Anziska Y , et al. Nerve conduction abnormalities in patients with MELAS and the A3243G mutation. Arch Neurol 2006; 63 (5) 746-748
• 69 Filosto M, Tomelleri G, Tonin P , et al. Neuropathology of mitochondrial diseases. Biosci Rep 2007; 27 (1-3) 23-30
• 70 DiMauro S, Hirano M. MELAS. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2010. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1233/ . Accessed September 12, 2013
• 71 DiMauro S, Hirano M. MERRF. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2009. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1520/ . Accessed September 12, 2013
• 72 DiMauro S, Hirano M. Mitochondrial DNA deletion syndromes. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2011. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1203/ . Accessed September 12, 2013
• 73 Rapin I, Suzuki K, Suzuki K, Valsamis MP. Adult (chronic) GM2 gangliosidosis. Atypical spinocerebellar degeneration in a Jewish sibship. Arch Neurol 1976; 33 (2) 120-130
• 74 Frey LC, Ringel SP, Filley CM. The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch Neurol 2005; 62 (6) 989-994
• 75 Mistry PK, Cappellini MD, Lukina E , et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol 2011; 86 (1) 110-115
• 76 Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010; 5: 16
• 77 Eng CM, Fletcher J, Wilcox WR , et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30 (2) 184-192
• 78 Goebel HH, Wisniewski KE. Current state of clinical and morphological features in human NCL. Brain Pathol 2004; 14 (1) 61-69
• 79 Schneider A, Nakagawa S, Keep R , et al. Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing. Am J Med Genet A 2009; 149A (11) 2444-2447
• 80 Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B, , eds. The Metabolic and Molecular Bases of Inherited Diseases. 8th ed. New York, NY: McGraw-Hill; 2001: 3733-74
• 81 Kaback MM, Desnick RJ. Hexosaminidase A deficiency. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2011. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1218/ . Accessed September 12, 2013
• 82 Pastores GM, Hughes DA. Gaucher disease. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2011. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1269/ . Accessed September 12, 2013
• 83 Patterson M. Niemann-Pick disease type C. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1296/ . Accessed September 12, 2013
• 84 Mehta A, Hughes DA. Fabry disease. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2011. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1292/ . Accessed September 12, 2013
• 85 Mole SE, Williams RE. Neuronal ceroid-lipofuscinoses. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1428/ . Accessed September 12, 2013
• 86 Walterfang M, Fahey M, Desmond P , et al. White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study. Neurology 2010; 75 (1) 49-56
• 87 Kornfeld M. Neuropathology of chronic GM2 gangliosidosis due to hexosaminidase A deficiency. Clin Neuropathol 2008; 27 (5) 302-308
• 88 Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 2004; 1685 (1-3) 48-62
• 89 Köhler W. Leukodystrophies with late disease onset: an update. Curr Opin Neurol 2010; 23 (3) 234-241
• 90 Keren Z, Falik-Zaccai TC. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. Pediatr Endocrinol Rev 2009; 7 (1) 6-11
• 91 van der Knaap MS, Pronk JC, Scheper GC. Vanishing white matter disease. Lancet Neurol 2006; 5 (5) 413-423
• 92 Hobson GM, Garbern JY. Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders. Semin Neurol 2012; 32 (1) 62-67
• 93 Cafferty MS, Lovelace RE, Hays AP, Servidei S, Dimauro S, Rowland LP. Polyglucosan body disease. Muscle Nerve 1991; 14 (2) 102-107
• 94 Stumpf E, Masson H, Duquette A , et al. Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by mutation in the glial fibrillary acid protein gene. Arch Neurol 2003; 60 (9) 1307-1312
• 95 Loes DJ, Fatemi A, Melhem ER , et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 2003; 61 (3) 369-374
• 96 Groeschel S, Kehrer C, Engel C , et al. Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. J Inherit Metab Dis 2011; 34 (5) 1095-1102
• 97 De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 2001; 124 (Pt 1) 121-131
• 98 Plecko B, Stöckler-Ipsiroglu S, Gruber S , et al. Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus Merzbacher phenotype. Neuropediatrics 2003; 34 (3) 127-136
• 99 Klein CJ, Boes CJ, Chapin JE , et al. Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome. Muscle Nerve 2004; 29 (2) 323-328
• 100 van der Knaap MS, Naidu S, Breiter SN , et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22 (3) 541-552
• 101 Wiesinger C, Kunze M, Regelsberger G, Forss-Petter S, Berger J. Impaired very long-chain acyl-CoA β-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction. J Biol Chem 2013; 288 (26) 19269-19279
• 102 Tan MA, Fuller M, Zabidi-Hussin ZA, Hopwood JJ, Meikle PJ. Biochemical profiling to predict disease severity in metachromatic leukodystrophy. Mol Genet Metab 2010; 99 (2) 142-148
• 103 Bruno C, Servidei S, Shanske S , et al. Glycogen branching enzyme deficiency in adult polyglucosan body disease. Ann Neurol 1993; 33 (1) 88-93
• 104 i Dali C, Hanson LG, Barton NW, Fogh J, Nair N, Lund AM. Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology 2010; 75 (21) 1896-1903
• 105 Takanashi J, Inoue K, Tomita M , et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002; 58 (2) 237-241
• 106 Shy ME, Hobson G, Jain M , et al. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 2003; 53 (3) 354-365
• 107 Kyllerman M, Rosengren L, Wiklund LM, Holmberg E. Increased levels of GFAP in the cerebrospinal fluid in three subtypes of genetically confirmed Alexander disease. Neuropediatrics 2005; 36 (5) 319-323
• 108 Steinberg SJ, Moser AB, Raymond GV. X-linked adrenoleukodystrophy. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2012. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1315/ . Accessed September 12, 2013
• 109 Fluharty AL. Arylsulfatase A deficiency. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2011. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1130/ . Accessed September 12, 2013
• 110 Gorospe JR. Alexander disease. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2010. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1172/ . Accessed September 12, 2013
• 111 Schiffmann R, Fogli A, Van der Knaap MS, Boespflug-Tanguy O. Childhood ataxia with central nervous system hypomyelination/vanishing white matter. GeneReviews [Internet]. 2012. Seattle, WA: University of Washington, Seattle; , Seattle. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1258/ . Accessed September 12, 2013
• 112 Hobson GM, Kamholz J. PLP1-related disorders. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; , Seattle; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1182/ . Accessed September 12, 2013
• 113 Klein CJ. Adult polyglucosan body disease. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2009. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK5300/ . Accessed September 12, 2013
• 114 Federico A, Dotti MT, Gallus GN. Cerebrotendinous xanthomatosis. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1409/ . Accessed September 12, 2013
• 115 Van Bogaert L. [The framework of the xanthomatoses and their different types. 2. Secondary xanthomatoses]. Rev Med Liege 1962; 17: 433-443
• 116 Wong K, Armstrong RC, Gyure KA , et al. Foamy cells with oligodendroglial phenotype in childhood ataxia with diffuse central nervous system hypomyelination syndrome. Acta Neuropathol 2000; 100 (6) 635-646
• 117 Jacob J, Robertson NJ, Hilton DA. The clinicopathological spectrum of Rosenthal fibre encephalopathy and Alexander's disease: a case report and review of the literature. J Neurol Neurosurg Psychiatry 2003; 74 (6) 807-810
• 118 Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35 (2) 235-242
• 119 Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T. MELAS and L-arginine therapy: pathophysiology of stroke-like episodes. Ann N Y Acad Sci 2010; 1201: 104-110
• 120 Taivassalo T, Haller RG. Implications of exercise training in mtDNA defects—use it or lose it?. Biochim Biophys Acta 2004; 1659 (2-3) 221-231
• 121 Eng CM, Guffon N, Wilcox WR , et al; International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. N Engl J Med 2001; 345 (1) 9-16
• 122 Rockenbach FJ, Deon M, Marchese DP , et al. The effect of bone marrow transplantation on oxidative stress in X-linked adrenoleukodystrophy. Mol Genet Metab 2012; 106 (2) 231-236
• 123 Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol 2004; 26 (1-2) 119-132
• 124 Polman CH, Reingold SC, Edan G , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58 (6) 840-846
• 125 Gascón-Bayarri J, Mañá J, Martínez-Yélamos S, Murillo O, Reñé R, Rubio F. Neurosarcoidosis: report of 30 cases and a literature survey. Eur J Intern Med 2011; 22 (6) e125-e132
• 126 Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78 (11) 1363-1368
• 127 Basu S, Alavi A. Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008; 10 (3) 131-137
• 128 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338 (5) 278-285
• 129 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (4) 655-661
• 130 Johnson KP, Brooks BR, Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45 (7) 1268-1276
• 131 Polman CH, O'Connor PW, Havrdova E , et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9) 899-910
• 132 Hartung HP, Gonsette R, König N , et al; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360 (9350) 2018-2025
• 133 Ances BM, Vitaliani R, Taylor RA , et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005; 128 (Pt 8) 1764-1777
• 134 Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis 2011; 53 (8) 836-842
• 135 Read PJ, Donovan B. Clinical aspects of adult syphilis. Intern Med J 2012; 42 (6) 614-620
• 136 Puéchal X. Whipple's disease. Ann Rheum Dis 2013; 72 (6) 797-803
• 137 Whiteman ML, Post MJ, Berger JR, Tate LG, Bell MD, Limonte LP. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993; 187 (1) 233-240
• 138 Roos KL. What I have learned about infectious diseases with my sleeves rolled up. Semin Neurol 2002; 22 (1) 9-15
• 139 Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol 2001; 20 (4) 146-155
• 140 Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11 (1) 1-17
• 141 Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D. Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis 2008; 47 (5) 659-667
• 142 Centers for Disease Control and Prevention ,Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55 (RR11) 1-94
• 143 Feurle GE, Junga NS, Marth T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. Gastroenterology 2010; 138 (2) 478-486 , quiz 11–12
• 144 Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4) 1-207 , quiz CE1–CE4
• 145 Vulliemoz S, Lurati-Ruiz F, Borruat FX , et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 2006; 77 (9) 1079-1082
• 146 Charness ME. Brain lesions in alcoholics. Alcohol Clin Exp Res 1993; 17 (1) 2-11
• 147 Ibrahim D, Froberg B, Wolf A, Rusyniak DE. Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med 2006; 26 (1) 67-97 , viii
• 148 Bledsoe BE. No more coma cocktails. Using science to dispel myths & improve patient care. JEMS 2002; 27 (11) 54-60
• 149 Chen R, Young GB. Metabolic encephalopathies. . In: Bolton CF, Young GB, , eds. London, England; Baillere's Clinical Neurology. 1996: 577
• 150 Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM 2010; 103 (1) 9-16
• 151 Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108 (9) 1458-1463
• 152 Bergman H, Daugirdas JT, Ing TS. Complications during hemodialysis. . In: Daugirdas JG, Blake PG, Ing TS, , eds. Handbook of Dialysis. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2001: 158
• 153 Strange K. Regulation of solute and water balance and cell volume in the central nervous system. J Am Soc Nephrol 1992; 3 (1) 12-27
• 154 Grossman H. Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 2003; 8 (11) 815-823
• 155 Spiegel J, Hellwig D, Becker G, Müller M. Progressive dementia caused by Hashimoto's encephalopathy — report of two cases. Eur J Neurol 2004; 11 (10) 711-713
• 156 Stern RA, Robinson B, Thorner AR, Arruda JE, Prohaska ML, Prange Jr AJ. A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996; 8 (2) 181-185
• 157 Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ 2008; 336 (7656) 1298-1302
• 158 Bilezikian JP, Khan AA, Potts Jr JT. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009; 94 (2) 335-339
• 159 Belanoff JK, Gross K, Yager A, Schatzberg AF. Corticosteroids and cognition. J Psychiatr Res 2001; 35 (3) 127-145
• 160 Hatipoglu BA. Cushing's syndrome. J Surg Oncol 2012; 106 (5) 565-571
• 161 Kothbauer-Margreiter I, Sturzenegger M, Komor J, Baumgartner R, Hess CW. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol 1996; 243 (8) 585-593
• 162 Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81 (6) 2036-2040
• 163 Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 2012; 77 (2) 200-206
• 164 Song TJ, Kim SJ, Kim GS, Choi YC, Kim WJ. The prevalence of thyrotoxicosis-related seizures. Thyroid 2010; 20 (9) 955-958
• 165 Oelkers W. Adrenal insufficiency. N Engl J Med 1996; 335 (16) 1206-1212
• 166 Nieman LK, Biller BM, Findling JW , et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93 (5) 1526-1540
• 167 Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust 1996; 164 (4) 200-203
• 168 Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab 2009; 94 (4) 1059-1067
• 169 Hemmer B, Glocker FX, Schumacher M, Deuschl G, Lücking CH. Subacute combined degeneration: clinical, electrophysiological, and magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry 1998; 65 (6) 822-827
• 170 Hegyi J, Schwartz RA, Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol 2004; 43 (1) 1-5
• 171 Kumar S. Vitamin B12 deficiency presenting with an acute reversible extrapyramidal syndrome. Neurol India 2004; 52 (4) 507-509
• 172 Weiss KH. Wilson disease. GeneReviews [Internet]. Seattle, WA:: University of Washington, Seattle; 2013. . Available at: http://www.ncbi.nlm.nih.gov/books/NBK1512/ . Accessed September 12, 2013
• 173 Bruha R, Marecek Z, Pospisilova L , et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 2011; 31 (1) 83-91
• 174 Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47 (6) 2089-2111
• 175 Butler CR, Bhaduri A, Acosta-Cabronero J , et al. Transient epileptic amnesia: regional brain atrophy and its relationship to memory deficits. Brain 2009; 132 (Pt 2) 357-368
• 176 Verstraeten E. Neurocognitive effects of obstructive sleep apnea syndrome. Curr Neurol Neurosci Rep 2007; 7 (2) 161-166
• 177 Dyken ME, Im KB. Obstructive sleep apnea and stroke. Chest 2009; 136 (6) 1668-1677
• 178 Epstein LJ, Kristo D, Strollo Jr PJ , et al; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5 (3) 263-276
• 179 Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery 2001; 49 (5) 1166-1184 , discussion 1184–1186
• 180 Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15 (1) 84-87
• 181 Dichgans M, Markus HS, Salloway S , et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008; 7 (4) 310-318
• 182 Vercelletto M, Boutoleau-Bretonnière C, Volteau C , et al; French research network on Frontotemporal dementia. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 2011; 23 (4) 749-759
• 183 Boxer AL, Knopman DS, Kaufer DI , et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013; 12 (2) 149-156
• 184 Pijnenburg YA, Sampson EL, Harvey RJ, Fox NC, Rossor MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry 2003; 18 (1) 67-72
• 185 Haase T. Early-onset dementia: the needs of younger people with dementia in Ireland. 2005 . Available at: http://www.alzheimer.ie/Alzheimer/media/SiteMedia/PDF%27s/Research/earlyOnsetDementia.PDF?ext=.pdf . Accessed June 17, 2013
• 186 Arai A, Matsumoto T, Ikeda M, Arai Y. Do family caregivers perceive more difficulty when they look after patients with early onset dementia compared to those with late onset dementia?. Int J Geriatr Psychiatry 2007; 22 (12) 1255-1261
• 187 Akman-Demir G, Serdaroglu P, Tasçi B. The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999; 122 (Pt 11) 2171-2182
• 188 Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades-Behçet's disease. Curr Opin Rheumatol 2006; 18 (1) 3-9